The knowledge of the mechanism underlying the cardiac damage in immunoglobulin light chain (LC) amyloidosis (AL) is essential to develop novel therapies and improve patients' outcome. Although an active role of reactive oxygen species (ROS) in LC-induced cardiotoxicity has already been envisaged, the actual mechanisms behind their generation remain elusive. This study was aimed at further dissecting the action of ROS generated by cardiotoxic LC in vivo and investigating whether transition metal ions are involved in this process. In the absence of reliable vertebrate model of AL, we used the nematode Caenorhabditis elegans, whose pharynx is an “ancestral heart.”
Results:
LC purified from patients with severe cardiac involvement intrinsically generated high levels of ROS and when administered to C. elegans induced ROS production, activation of the DAF-16/forkhead transcription factor (FOXO) pathway, and expression of proteins involved in stress resistance and survival. Profound functional and structural ROS-mediated mitochondrial damage, similar to that observed in amyloid-affected hearts from AL patients, was observed. All these effects were entirely dependent on the presence of metal ions since addition of metal chelator or metal-binding 8-hydroxyquinoline compounds (chelex, PBT2, and clioquinol) permanently blocked the ROS production and prevented the cardiotoxic effects of amyloid LC.
Innovation and Conclusion:
Our findings identify the key role of metal ions in driving the ROS-mediated toxic effects of LC. This is a novel conceptual advance that paves the way for new pharmacological strategies aimed at not only counteracting but also totally inhibiting the vicious cycle of redox damage. Antioxid. Redox Signal. 27, 567–582.
Get full access to this article
View all access options for this article.
References
1.
AdlardPA, ChernyRA, FinkelsteinDI, GautierE, RobbE, CortesM, VolitakisI, LiuX, SmithJP, PerezK, LaughtonK, LiQX, CharmanSA, NicolazzoJA, WilkinsS, DelevaK, LynchT, KokG, RitchieCW, TanziRE, CappaiR, MastersCL, BarnhamKJ, and BushAI. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 59: 43–55, 2008.
2.
AnbalaganC, LafayetteI, Antoniou-KourouniotiM, HaqueM, KingJ, JohnsenB, BaillieD, GutierrezC, MartinJA, and de PomeraiD. Transgenic nematodes as biosensors for metal stress in soil pore water samples. Ecotoxicology, 21: 439–455, 2012.
3.
AveryL and HorvitzHR. Pharyngeal pumping continues after laser killing of the pharyngeal nervous system of C. elegans. Neuron, 3: 473–485, 1989.
4.
BackP, BraeckmanBP, and MatthijssensF. ROS in aging Caenorhabditis elegans: damage or signaling?. Oxid Med Cell Longev, 2012: 608478, 2012.
5.
BarnhamKJ and BushAI. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem Soc Rev, 43: 6727–6749, 2014.
6.
BhatlaN and HorvitzHR. Light and hydrogen peroxide inhibit C. elegans Feeding through gustatory receptor orthologs and pharyngeal neurons. Neuron, 85: 804–818, 2015.
7.
BoydWA, ColeRD, AndersonGL, and WilliamsPL. The effects of metals and food availability on the behavior of Caenorhabditis elegans. Environ Toxicol Chem, 22: 3049–3055, 2003.
8.
BrennerDA, JainM, PimentelDR, WangB, ConnorsLH, SkinnerM, ApsteinCS, and LiaoR. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res, 94: 1008–1010, 2004.
9.
ChavezV, Mohri-ShiomiA, MaadaniA, VegaLA, and GarsinDA. Oxidative stress enzymes are required for DAF-16-mediated immunity due to generation of reactive oxygen species by Caenorhabditis elegans. Genetics, 176: 1567–1577, 2007.
10.
ChinTF and LachJL. Drug diffusion and bioavailability: tetracycline metallic chelation. Am J Hosp Pharm, 32: 625–629, 1975.
11.
CrouchPJ, SavvaMS, HungLW, DonnellyPS, MotAI, ParkerSJ, GreenoughMA, VolitakisI, AdlardPA, ChernyRA, MastersCL, BushAI, BarnhamKJ, and WhiteAR. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem, 119: 220–230, 2011.
12.
DavisDP, GalloG, VogenSM, DulJL, SciarrettaKL, KumarA, RaffenR, StevensFJ, and ArgonY. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain. J Mol Biol, 313: 1021–1034, 2001.
13.
DiomedeL, RognoniP, LavatelliF, RomeoM, del FaveroE, CantuL, GhibaudiE, di FonzoA, CorbelliA, FiordalisoF, PalladiniG, ValentiniV, PerfettiV, SalmonaM, and MerliniG. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 123: 3543–3552, 2014.
14.
DispenzieriA, GertzMA, KyleRA, LacyMQ, BurrittMF, TherneauTM, GreippPR, WitzigTE, LustJA, RajkumarSV, FonsecaR, ZeldenrustSR, McGregorCG, and JaffeAS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol, 22: 3751–3757, 2004.
FonteV, KapulkinWJ, TaftA, FluetA, FriedmanD, and LinkCD. Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc Natl Acad Sci U S A, 99: 9439–9444, 2002.
17.
FriedlyJC, KentDB, and DavisJA. Simulation of the mobility of metal-EDTA complexes in groundwater: the influence of contaminant metals. Environ Sci Technol, 36: 355–363, 2002.
18.
GaetaA and HiderRC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol, 146: 1041–1059, 2005.
19.
GertzMA, ComenzoR, FalkRH, FermandJP, HazenbergBP, HawkinsPN, MerliniG, MoreauP, RoncoP, SanchorawalaV, SezerO, SolomonA, and GrateauG. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol, 79: 319–328, 2005.
20.
GiglioMP, HunterT, BannisterJV, BannisterWH, and HunterGJ. The manganese superoxide dismutase gene of Caenorhabditis elegans. Biochem Mol Biol Int, 33: 37–40, 1994.
21.
GuanJ, MishraS, QiuY, ShiJ, TrudeauK, LasG, LiesaM, ShirihaiOS, ConnorsLH, SeldinDC, FalkRH, MacRaeCA, and LiaoR. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med, 6: 1493–1507, 2014.
22.
HarringtonJM, BoydWA, SmithMV, RiceJR, FreedmanJH, and CrumblissAL. Amelioration of metal-induced toxicity in Caenorhabditis elegans: utility of chelating agents in the bioremediation of metals. Toxicol Sci, 129: 49–56, 2012.
23.
HartwigK, HeidlerT, MochJ, DanielH, and WenzelU. Feeding a ROS-generator to Caenorhabditis elegans leads to increased expression of small heat shock protein HSP-16.2 and hormesis. Genes Nutr, 4: 59–67, 2009.
24.
HeQ, SongN, XuH, WangR, XieJ, and JiangH. Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J Neural Transm, 118: 397–406, 2011.
25.
HunterT, BannisterWH, and HunterGJ. Cloning, expression, and characterization of two manganese superoxide dismutases from Caenorhabditis elegans. J Biol Chem, 272: 28652–28659, 1997.
26.
Huntington Study Group ReachHDI.Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol, 14: 39–47, 2015.
27.
ImbertJ, CulottaV, FurstP, GedamuL, and HamerD. Regulation of metallothionein gene transcription by metals. Adv Inorg Biochem, 8: 139–164, 1990.
LavatelliF, ImperliniE, OrruS, RognoniP, SarnataroD, PalladiniG, MalpassoG, SorianoME, Di FonzoA, ValentiniV, GnecchiM, PerliniS, SalvatoreF, and MerliniG. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB J, 29: 4614–4628, 2015.
30.
LiaoR, JainM, TellerP, ConnorsLH, NgoyS, SkinnerM, FalkRH, and ApsteinCS. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation, 104: 1594–1597, 2001.
31.
MangoSE.The C. elegans pharynx: a model for organogenesis. WormBook. 1–26, 2007.
32.
MatlackKE, TardiffDF, NarayanP, HamamichiS, CaldwellKA, CaldwellGA, and LindquistS. Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. Proc Natl Acad Sci U S A, 111: 4013–4018, 2014.
33.
MerliniG and BellottiV. Molecular mechanisms of amyloidosis. N Engl J Med, 349: 583–596, 2003.
34.
MerliniG and PalladiniG. Light chain amyloidosis: the heart of the problem. Haematologica, 98: 1492–1495, 2013.
35.
MishraS, GuanJ, PlovieE, SeldinDC, ConnorsLH, MerliniG, FalkRH, MacRaeCA, and LiaoR. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol, 305: H95–H103, 2013.
36.
Moreno-ArriolaE, Cardenas-RodriguezN, Coballase-UrrutiaE, Pedraza-ChaverriJ, Carmona-AparicioL, and Ortega-CuellarD. Caenorhabditis elegans: a useful model for studying metabolic disorders in which oxidative stress is a contributing factor. Oxid Med Cell Longev, 2014: 705253, 2014.
37.
MukhopadhyayA, OhSW, and TissenbaumHA. Worming pathways to and from DAF-16/FOXO. Exp Gerontol, 41: 928–934, 2006.
38.
MundayR, MundayCM, and WinterbournCC. Inhibition of copper-catalyzed cysteine oxidation by nanomolar concentrations of iron salts. Free Radic Biol Med, 36: 757–764, 2004.
39.
NuvoloneM and MerliniG.Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant, 2016 [Epub ahead of print] DOI: 10.1093/ndt/gfw305.
40.
OggS, ParadisS, GottliebS, PattersonGI, LeeL, TissenbaumHA, and RuvkunG. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature, 389: 994–999, 1997.
41.
Ostrerova-GoltsN, PetrucelliL, HardyJ, LeeJM, FarerM, and WolozinB. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci, 20: 6048–6054, 2000.
42.
PerfettiV, SassanoM, UbbialiP, VignarelliMC, ArbustiniE, CortiA, and MerliniG. Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. Anal Biochem, 239: 107–109, 1996.
43.
PillaiJA.Neurodegenerative Diseases: Unifying Principles, edited by CummingsJL. Northants, United Kingdom: Oxford University Press, 2016.
44.
PrachayasittikulV, PrachayasittikulS, RuchirawatS, and PrachayasittikulV. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther, 7: 1157–1178, 2013.
45.
RebolledoDL, AldunateR, KohnR, NeiraI, MinnitiAN, and InestrosaNC. Copper reduces Abeta oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis. J Neurosci, 31: 10149–10158, 2011.
46.
RognoniP, LavatelliF, CasariniS, PalladiniG, VergaL, PedrazzoliP, ValentiniG, MerliniG, and PerfettiV. A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. PLoS One, 8: e76022, 2013.
47.
ShtondaB and AveryL. CCA-1, EGL-19 and EXP-2 currents shape action potentials in the Caenorhabditis elegans pharynx. J Exp Biol, 208: 2177–2190, 2005.
48.
StarichTA, LeeRY, PanzarellaC, AveryL, and ShawJE. eat-5 and unc-7 represent a multigene family in Caenorhabditis elegans involved in cell-cell coupling. J Cell Biol, 134: 537–548, 1996.
49.
StoilovaT, ColomboL, ForloniG, TagliaviniF, and SalmonaM. A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem, 56: 5987–6006, 2013.
50.
ValentiniS, CabreiroF, AckermanD, AlamMM, KunzeMB, KayCW, and GemsD. Manipulation of in vivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans. Mech Ageing Dev, 133: 282–290, 2012.
51.
WakabayashiT, NakamuraN, SambongiY, WadaY, OkaT, and FutaiM. Identification of the copper chaperone, CUC-1, in Caenorhabditis elegans: tissue specific co-expression with the copper transporting ATPase, CUA-1. FEBS Lett, 440: 141–146, 1998.
52.
WechalekarA, WhelanC, LachmannH, FontanaM, MahmoodS, GillmoreJD, and HawkinsPN. Oral doxycycline improves outcomes of stage III AL amyloidosis—a matched case control study. Blood, 126: 732–732, 2015.
53.
WechalekarA, WhelanC, SachchithananthamS, FontanaM, MahmoodS, FoardD, LaneT, LachmannHJ, GillmoreJD, and HawkinsPN. A matched case control study of doxycycline added to chemotherapy for reducing early mortality in patients with advanced cardiac AL amyloidosis from the alchemy study cohort. Blood, 124: 3485–3485, 2014.
54.
WinterbournCC and CarrellRW. Oxidation of human haemoglobin by copper. Mechanism and suggested role of the thiol group of residue beta-93. Biochem J, 165: 141–148, 1977.
55.
WongBX and DuceJA. The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front Pharmacol, 5: 81, 2014.
56.
AltunZF and HallDH. Handbook of C. elegans Anatomy. In: WormAtlas. www.wormatlas.org/hermaphrodite/pharynx/Phaframeset.html.2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
